A Phase III Study of Durvalumab Immunotherapy with Chemotherapy as Initial Treatment for Advanced Pleural Mesothelioma

Share
Print

Full Title

DREAM3R: DuRvalumab (MEDI4736) with chEmotherapy as first line treAtment in advanced pleural Mesothelioma - A phase 3 Randomised trial (WIRB)

Purpose

The purpose of this study is to see if adding the immunotherapy drug durvalumab to standard chemotherapy is more effective than standard chemotherapy alone (pemetrexed and cisplatin) in patients starting treatment for advanced pleural mesothelioma. All patients will receive standard chemotherapy, and two-thirds of them will be randomly assigned to receive durvalumab. The medications in this study are all given intravenously (by vein).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have advanced inoperable pleural mesothelioma.
  • Patients may not have received prior chemotherapy or immunotherapy for mesothelioma.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self-care, and capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Marjorie Zauderer at 646-608-3790.

Protocol

21-237

Phase

III

Investigator

Co-Investigators